Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SVR & Risk of T2D Among Patients with HCV

J Viral Hepat; ePub 2018 Feb 25; Li, Zhang, et al

Among a large US cohort of patients treated for hepatitis C virus (HCV), patients who achieved sustained virological response (SVR) demonstrated a substantially lower risk for development of type 2 diabetes mellitus (T2D) than patients with treatment failure. This according to a study that examined how response to HCV treatment impacts risk of subsequent T2D. Among HCV patients without a history of T2D or hepatitis B, researchers investigated incidence of T2D from 12 weeks post-HCV-treatment through December 2015. They found:

  • Among 5,127 patients with an average follow-up of 3.7 years, T2D incidence was significantly lower among patients who achieved SVR than among patients with treatment failure (6.2% vs 21.7%).
  • Risk of T2D was higher among African American and Asian American patients vs white patients (adjusted hazard ratio [aHR], 1.82 and 1.75, respectively).
  • Patients with body mass index (BMI) ≥30 and 25-20 demonstrated higher risk than those with BMI <25.
  • Cirrhosis at baseline was also a risk factor.

Citation:

Li J, Zhang T, Gordon SC, et al. Impact of sustained virological response on risk of type 2 diabetes among hepatitis C patients in the US. [Published online ahead of print February 25, 2018]. J Viral Hepat. doi:10.1111/jvh.12887.

This Week's Must Reads

Relevance of Health Literacy to CV Health, Circulation; ePub 2018 Jun 4; Magnani, et al

Diabetes & Long-Term Kidney Disease, Diabetes Care; ePub 2018 Jun 1; Warren, et al

Maternal Loss of Control Over Eating, Am J Clin Nutr; ePub 2018 Jun 5; Micali, et al

Efficacy of Brief Behavioral Treatment for Insomnia, Sleep Medicine; ePub 2018 Jun 2; McCrae, et al

Opioid-Related Adverse Events in Surgical Patients, JAMA Surg; ePub 2018 May 23; Shafi, et al

Must Reads in Hepatitis

Glecaprevir/pibrentasvir Can Reduce HCV Tx Duration, Hepatol Int; ePub 2018 May 29; Abutaleb, et al

Estimates of HCV by Race and Sex in US, BMC Infect Dis; ePub 2018 May 16; Hall, et al

Efficacy of DAA Therapy for HCV in Older Adults, J Am Geriatr Soc; ePub 2018 May 25; Mazzarelli, et al

HCV Treatment in People Who Inject Drugs, Open Forum Infect Dis; ePub 2018 May 23; Alimohammadi, et al

Risk of HCV Among Vulnerable Populations, J Viral Hepat; ePub 2018 May 31; Aisyah, et al